Tumor lysis syndrome associated with weekly paclitaxel treatment in a case with ovarian cancer
Tumor lysis syndrome associated with weekly paclitaxel treatment in a case with ovarian cancer
复制标题
DOI：
10.1016/j.ygyno.2006.06.003
复制
发表时间：
2006-11-01
影响因子：
4.7
通讯作者：
Tanaka, Kenichi
中科院分区：
文献类型：
--
作者：
Yahata, Tetsuro;Nishikawa, Nobumichi;Tanaka, Kenichi
背景。肿瘤溶解综合征（TLS）的特征是由于恶性细胞的快速肿瘤溶解（通常在化疗后）导致的生化变化，例如高尿酸血症和高钾血症。 TLS 是非血液恶性肿瘤中一种罕见的并发症。案例。一名 53 岁女性因复发性卵巢癌伴大量腹水而每周静脉注射紫杉醇。服用紫杉醇五天后，患者出现 TLS。她对剧烈静脉补液、速尿、别嘌呤醇和碳酸氢钠的适当治疗反应良好。结论。本病例报告描述了第一位因卵巢癌服用紫杉醇后出现 TLS 的患者。我们的病例极为特殊，因为对于相对不敏感的肿瘤类型，在没有任何危险因素的情况下，低剂量紫杉醇给药后发生了 TLS。 (c) 2006 Elsevier Inc. 保留所有权利。
Background. Tumor lysis syndrome (TLS) is characterized by biochemical changes such as hyperuricemia and hyperkalemia due to rapid tumor lysis of malignant cells, usually after chemotherapy. TLS is a rare complication in nonhematological malignancies.Case. A 53-year-old female received intravenous weekly paclitaxel for recurrent ovarian cancer with massive ascites. Five days following the administration of paclitaxel, the patient developed TLS. She responded well to appropriate treatment with a combination of vigorous intravenous hydration, furosemide, allopurinol, and sodium bicarbonate.Conclusion. This case report describes the first patient to develop TLS following paclitaxel administration for ovarian cancer. Our case is extremely exceptional because TLS occurred after the low dosage administration of paclitaxel for relatively insensitive tumor types without any risk factors. (c) 2006 Elsevier Inc. All rights reserved.